{"schema_version":"secwatch.filing_event.v1","accession":"0001842952-22-000004","form_type":"8-K","ticker":"CNTX","cik":"0001842952","company_name":"Context Therapeutics Inc.","filed_at":"2022-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.784257+00:00","generated_at":"2026-06-27T20:43:55.327387+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Context Therapeutics announces leadership changes: Rencher retires, Beck and Fletcher appointed","bullets":["Bill Rencher, Ph.D., retired as Head of CMC effective Jan 1, 2022; transitions to advisory role at $8,000/month through Apr 2022.","Christopher Beck appointed SVP, Operations; previously VP of Program Management at Galera Therapeutics.","Mark Fletcher, Ph.D., appointed VP, R&D; previously VP of Product Development at Pharmaceutical Associates, Inc.","Appointments aim to advance lead candidate onapristone extended release (ONA-XR) in breast, ovarian, and endometrial cancers.","Rencher's retirement was planned, not due to disagreement; advisory role continues through October 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001842952-22-000004","json":"https://secwatch.observer/filing/0001842952-22-000004.json","markdown":"https://secwatch.observer/filing/0001842952-22-000004.md","text":"https://secwatch.observer/filing/0001842952-22-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1842952/000184295222000004/0001842952-22-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1842952/000184295222000004/cntx-20220101.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T20:43:55.327387+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fc752d3b5f","claim":"Bill Rencher retired as Head of Chemistry Manufacturing Controls at Context Therapeutics Inc..","evidence_excerpt":"As of January 1, 2022, Bill Rencher, Ph.D., retired as Head of Chemistry Manufacturing Controls of Context Therapeutics Inc. (the “Company”), and transitioned into an advisory role with the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1842952/000184295222000004/0001842952-22-000004-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"Head of Chemistry Manufacturing Controls"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}